Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glybera Registry, Long-term Safety and Efficacy Follow-up in Lipoprotein Lipase Deficient (LPLD) Patients Treated With Alipogene Tiparvovec (GLYBERA®)

NCT03293810 is registered in ClinicalTrials.gov with UniQure Biopharma B.V. as lead sponsor.

NCT NCT03293810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03293810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glybera Registry, Long-term Safety and Efficacy Follow-up in Lipoprotein Lipase Deficient (LPLD) Patients Treated With Alipogene Tiparvovec (GLYBERA®)
Lead sponsor
UniQure Biopharma B.V.
Phase
Observational
Overall status
Completed
Start date
June 27, 2014
Completion date
June 30, 2023
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

familial hyperchylomicronemia, familial hyperlipoproteinemia type 1, lipoprotein lipase deficiency